Sign Up
Stories
Diabetes Drug Markets' Growth and Dominance
Share
Biopharma Innovations and FDA Decisions
Eli Lilly to Build $2.5B Plant for Weigh...
Eli Lilly's Diabetes and Obesity Unit Le...
ANJESO Drug Insight and Market Forecast
Albumin Excipient Market Growth
Amgen's Obesity Prospects and Q4 Results...
Overview
API
Sulfonylureas market in North America projected to grow from USD 3.05 billion in 2023 to around USD 3.35 billion by 2028, driven by increasing demand for effective diabetes management and the high incidence of diabetes in the US. Meanwhile, the China diabetes care drugs market is expected to reach USD 13.73 billion by 2028, with oral anti-diabetic drugs dominating the market. Additionally, the North America oral anti-diabetic drug market is projected to reach a valuation of USD 22.54 billion by 2028, with metformin maintaining its dominance.
Ask a question
How might the projected growth of diabetes drug markets impact healthcare systems and policies in North America and China?
In what ways could the dominance of oral anti-diabetic drugs influence the development of new pharmaceuticals and treatment approaches for diabetes?
What challenges and opportunities arise for pharmaceutical companies, healthcare providers, and policymakers in adapting to the evolving diabetes care landscape?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Jan 2024
Coverage